8-K
filed June 11, 2024, 7:59 PM ET
CIK 0001501756
leadership
confidence high
sentiment neutral
materiality 0.40
Adverum appoints Rabia Ozden as CMO, Szilard Kiss to board, effective June 10
Adverum Biotechnologies, Inc.
- Rabia Gurses Ozden, M.D. appointed Chief Medical Officer effective June 10, 2024.
- Ozden resigned from the Board and R&D Committee effective same date.
- Szilard Kiss, M.D. appointed as Class III director; expected to join R&D Committee.
- Kiss is a retina specialist, professor at Weill Cornell, and CMO of Blue Gen Therapeutics.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rabia Gurses Ozden, M.D. was appointed as Chief Medical Officer at Adverum Biotechnologies, Inc..
- Action
- appointed
- Role
- Chief Medical Officer
Exact text from the filing
appointed Rabia Gurses Ozden, M.D. as the Company’s Chief Medical Officer
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Rabia Gurses Ozden, M.D. resigned as Director at Adverum Biotechnologies, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
Dr. Ozden notified the Board of her decision to resign from the Board and the Research and Development Committee of the Board, effective June 10, 2024.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Szilárd Kiss, M.D. was appointed as Director at Adverum Biotechnologies, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
appointed Szilárd Kiss, M.D. as a director to fill the vacancy on the Board created by Dr. Ozden’s resignation.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.